In Vivo is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Akzo Nobel scraps plan to divest Organon through IPO

Executive Summary

Dutch chemical giant Akzo Nobel plans to spin off 20-30% of its Organon NV pharmaceutical subsidiary in an IPO on Amsterdam's Euronext exchange. Some analysts estimate the offering will value Organon between €8-9bn ($10.2-11.5bn).
Deal Industry
  • Pharmaceuticals
Deal Status
  • Withdrawn
Deal Type
  • Financing
    • IPO
    • Spin-Off

Related Companies